Clinical Trial Update: Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase I trial evaluating AZD1775 in combination with belinostat for relapsed or refractory myeloid malignancies or untreated acute myeloid leukemia has been ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Post Cytotoxic Therapy
• Chronic Myeloid Leukemia Bcr-abl1 Positive
• Chronic Myeloid Leukemia Bcr-abl1 Positive Blast Phase
• Myelodysplastic Syndrome

Drugs mentioned

• AZD1775 (adavosertib) (adavosertib)
• Belinostat (belinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 1 | Status: TERMINATED